wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1063.
1 2 3 4 5 ... 22 Next »

Medicine/Pharmacology
23.03.2017
Alcon receives US FDA approval for new AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction
Alcon receives US FDA approval for new AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction The unique optical desig
Medicine/Pharmacology
22.03.2017
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure   Novartis remains committed to improving and extending the lives of patients with cardiovascular disease and will continue to invest in ways to improve their outcomes Basel, March 22, 2017 - Novartis today announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX030 (serelaxin) in patients with acute heart failure (AHF).
Medicine/Pharmacology - Administration/Government
21.03.2017
Novartis’ Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment   Patients with longer disease duration before treatment with Co
Medicine/Pharmacology - Administration/Government
18.03.2017
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs.
Life Sciences - Medicine/Pharmacology
17.03.2017
Cut the long story short - and stitch it back together
Cut the long story short - and stitch it back together
Media releases, information for representatives of the media Media Relations (E) A species of unicellular ciliate has found a special trick to make use of the cellular machinery in seemingly impossible ways.
Medicine/Pharmacology - Computer Science/Telecom
14.03.2017
Is Reliable Artificial Intelligence Possible?
Is Reliable Artificial Intelligence Possible?
In the quest for reliable artificial intelligence, EPFL scientist Marcel Salathé argues that AI technology should be openly available.
Medicine/Pharmacology - Physics/Materials Science
14.03.2017
Rays of hope for patients
Rays of hope for patients
Tumours of the eye are rare. Yet for those affected, they mean a stroke of fate that involves not only the loss of vision but often the whole eye as well.
Medicine/Pharmacology
13.03.2017
Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines.
Medicine/Pharmacology - Life Sciences
13.03.2017
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor Approved based on a first-line P
Medicine/Pharmacology - Life Sciences
13.03.2017
Joint Efforts Towards Treating Paralysis
EPFL scientists Stéphanie Lacour and Grégoire Courtine report on the status of their research and share their vision about the future of wearable neuroprosthetics at this year's edition of South by South West in Austin, Texas, on March 12 th .
Medicine/Pharmacology
09.03.2017
People who Trust Their Doctor Tend to Feel Better
Confidence in doctors, therapists and nursing staff leads to an improvement in subjectively perceived complaints, satisfaction and quality of life in patients. This is the conclusion of a meta-analysis by psychologists at the University of Basel, published in the journal PLOS ONE. Trust in doctors, therapists and nursing staff is a key requirement when treating patients, and is already laid down as a principle in the ethical guidelines and professional codes of each clinical field.
Medicine/Pharmacology - Life Sciences
06.03.2017
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira * Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis Study reinforces strength of Sandoz pipeline and its key role in the broader Novartis immunology portfolio Holzkirchen, 6 March 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today presented data for its proposed biosimilar adalimumab (GP2017).
Medicine/Pharmacology
06.03.2017
Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
New analysis shows 94% of patients on Cosentyx regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment   Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin (PASI 90 to 100) ,   Cosentyx has treated 80,000 patients worldwide to date and is the only IL-17A inhibitor approved in psoriasis, psoriatic arthritis and ankylo
Medicine/Pharmacology - Administration/Government
02.03.2017
Roche’s Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Phase III APHINITY study shows Roche's Perjeta regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin and chemotherapy
Medicine/Pharmacology - Administration/Government
01.03.2017
Better health services for the chronically ill
Better health services for the chronically ill
The SNSF is launching the National Research Programme ‘Smarter Health Care'. 29 research teams will be looking for ways of providing better and more cost-efficient health services for people with chronic diseases.
Life Sciences - Medicine/Pharmacology
28.02.2017
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Stem cells derived neuronal networks grown on a chip as an alternative to animal testing
Media releases, information for representatives of the media Media Relations (E) Scientists at the Institute for Infectious Diseases, University of Bern have developed an in vitro stem cell-based bio
Medicine/Pharmacology - Life Sciences
24.02.2017
Novartis receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients with B
Medicine/Pharmacology - Life Sciences
23.02.2017
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.
Medicine/Pharmacology - Mechanical Engineering/Mechanics
21.02.2017
Innovation cannot be taught; it must be learned
Innovation cannot be taught; it must be learned
ETH President Lino Guzzella welcomed Alexander van der Bellen to the University on Friday, where the Austrian President was shown how ETH is encouraging innovation.
Environment/Sustainable Development - Medicine/Pharmacology
21.02.2017
Selenium deficiency promoted by climate change
Selenium deficiency promoted by climate change
As a result of climate change, concentrations of the trace element selenium in soils are likely to decrease.
Medicine/Pharmacology - Life Sciences
18.02.2017
Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Proof of concept study in first line mRCC (a type of kidney cancer) shows that TECENTRIQ and Avastin can be combined with a manageable safety profile Study results also showed encouraging efficacy compared to sunitinib in those people whose disease expressed the PD-L1 (programmed de
Computer Science/Telecom - Medicine/Pharmacology
06.02.2017
Switzerland Launches a National Center for Data Science
Switzerland Launches a National Center for Data Science
Switzerland is creating a National Center for Data Science to foster innovation in data science, multidisciplinary research and open science.
Medicine/Pharmacology - Life Sciences
31.01.2017
Novartis drug Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC)   Approval addresses unmet need as up
Medicine/Pharmacology - Life Sciences
27.01.2017
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Cellestia Biotech, an EPFL spin-off, can now carry out clinical trials on its new cancer treatment after raising CHF 8 million in seed money.
Life Sciences - Medicine/Pharmacology
26.01.2017
LSD alters perception via serotonin receptors
Humans perceive everyday things and experiences differently and attach different meaning to pieces of music, for instance. In the case of psychiatric disorders, this perception is often altered. For patients suffering from addictions, for instance, drug stimuli are more meaningful than for people without an addiction.
Medicine/Pharmacology
26.01.2017
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
Innovative AcrySof IQ PanOptix Toric i ntraocular lens (IOL) extends Alcon's trifocal PanOptix IOL portfolio to a wider range of patients   CE-marked in November 2016, this IOL offers excellent near
Medicine/Pharmacology - Environment/Sustainable Development
26.01.2017
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program   Novartis improved position in key sust
Medicine/Pharmacology - Business/Economics
26.01.2017
Inability to Work: Medical Experts Often Disagree
Independent medical evaluations are often used to adjudicate disability claims. But different doctors assessing the same patient often disagree on whether the patient is disabled or not. This problem can be mitigated by applying standardized procedures, says an international study led by researchers at the University of Basel and the University Hospital Basel in Switzerland.
Business/Economics - Medicine/Pharmacology
25.01.2017
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback FY net sales (0% cc ) in line with prior year due to st
Life Sciences - Medicine/Pharmacology
23.01.2017
Immune Defense Without Collateral Damage
Immune Defense Without Collateral Damage
Researchers from the University of Basel in Switzerland have clarified the role of the enzyme MPO. In fighting infections, this enzyme, which gives pus its greenish color, produces a highly aggressive acid that can kill pathogens without damaging the surrounding tissue. In the human body's fight against bacterial pathogens, white blood cells are in the front line.
Life Sciences - Medicine/Pharmacology
20.01.2017
Cell fate regulation by LIN41: activity determined by binding location
Helge Großhans and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mode of action of the RNA-binding protein and stem cell factor LIN41. In an animal model, they showed that LIN41 silences four specific mRNAs, by two distinct mechanisms. They found that the choice of mechanism is determined by where on the mRNA LIN41 binds.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
16.01.2017
Every Meal Triggers Inflammation
When we eat, we do not just take in nutrients - we also consume a significant quantity of bacteria. The body is faced with the challenge of simultaneously distributing the ingested glucose and fighting these bacteria.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Medicine/Pharmacology - Physics/Materials Science
03.01.2017
Looking back at 2016 (2/2)
Looking back at 2016 (2/2)
Slowing the aging process, improving data security, enabling paraplegics to walk again, transporting vaccines at room temperature to warm countries, creating jobs with the CHF 400 million raised by spin-offs - those are just some of the many areas where EPFL scientists have made a lasting contribution.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Environment/Sustainable Development
23.12.2016
Fighting cholera by predicting how its spreads
Fighting cholera by predicting how its spreads
In October, EPFL and Médecins Sans Frontières joined forces in an unprecedented effort to predict how the cholera epidemic in Haiti will spread.
Psychology - Medicine/Pharmacology
22.12.2016
Helping pays off: People who care for others live longer
Older people who help and support others live longer. These are the findings of a study published in the journal ‘Evolution and Human Behavior', conducted by researchers from the University of Basel, Edith Cowan University, the University of Western Australia, the Humboldt University of Berlin, and the Max Planck Institute for Human Development in Berlin.
Medicine/Pharmacology
22.12.2016
Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with haemophilia A an
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
1 2 3 4 5 ... 22 Next »